{"id":"standard-dose-of-hcq","safety":{"commonSideEffects":[{"rate":null,"effect":"Retinopathy"},{"rate":"5–10","effect":"Gastrointestinal disturbance (nausea, diarrhea)"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Pruritus"},{"rate":null,"effect":"Cardiomyopathy (rare, with long-term use)"}]},"_chembl":{"chemblId":"CHEMBL664","moleculeType":"Small molecule","molecularWeight":"176.22"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"HCQ concentrates in acidic cellular compartments and interferes with endosomal toll-like receptor activation, particularly TLR7 and TLR9, thereby suppressing interferon production and B-cell activation. It also inhibits phospholipase C and reduces calcium signaling, contributing to its broad immunosuppressive and anti-inflammatory effects. These mechanisms make it effective in autoimmune and rheumatologic conditions.","oneSentence":"Hydroxychloroquine is a quinoline antimalarial that accumulates in lysosomes and inhibits toll-like receptor signaling and antigen presentation, reducing inflammatory and autoimmune responses.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:09:12.541Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Systemic lupus erythematosus (SLE)"},{"name":"Rheumatoid arthritis"},{"name":"Malaria prophylaxis and treatment"},{"name":"Sjögren's syndrome"}]},"trialDetails":[{"nctId":"NCT07497282","phase":"PHASE2","title":"Venlafaxine as Adjunct Therapy in Rheumatoid Arthritis","status":"NOT_YET_RECRUITING","sponsor":"Ain Shams University","startDate":"2026-03-26","conditions":"Rheumatoid Arthritis","enrollment":70},{"nctId":"NCT07467252","phase":"PHASE2","title":"AIPH-TB: AI-Optimised Pyrazinamide-Hydroxychloroquine vs Standard RIPE for Drug-Sensitive Pulmonary Tuberculosis - A Phase II RCT","status":"NOT_YET_RECRUITING","sponsor":"Ministry of Health, Saudi Arabia","startDate":"2026-09","conditions":"Pulmonary Tuberculosis","enrollment":200},{"nctId":"NCT06037811","phase":"PHASE2","title":"Early Adalimumab Induction for Immune Checkpoint Inhibitor Associated Inflammatory Arthritis","status":"RECRUITING","sponsor":"Tom Appleton","startDate":"2024-04-15","conditions":"Inflammatory Arthritis, Immune-related Adverse Event","enrollment":30},{"nctId":"NCT05782335","phase":"","title":"Analysis of T and B Cell Repertoire Changes in Response to Orencia® (Abatacept) in Rheumatoid Arthritis","status":"RECRUITING","sponsor":"Hospital for Special Surgery, New York","startDate":"2022-11-01","conditions":"Rheumatoid Arthritis","enrollment":72},{"nctId":"NCT07077486","phase":"PHASE4","title":"Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-08-25","conditions":"Lupus or SLE, Interstitial Lung Disease, Systemic Lupus Erythematosus","enrollment":100},{"nctId":"NCT05576896","phase":"PHASE2","title":"Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory","status":"RECRUITING","sponsor":"Northwestern University","startDate":"2022-10-10","conditions":"Stage IV Colorectal Cancer Positive for BRAF V600E Mutation, Colorectal Cancer, Colorectal Cancer Stage IV","enrollment":43},{"nctId":"NCT03037437","phase":"PHASE2","title":"Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2017-02-16","conditions":"Hepatocellular Cancer","enrollment":64},{"nctId":"NCT07138898","phase":"PHASE2","title":"Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty","status":"NOT_YET_RECRUITING","sponsor":"NYU Langone Health","startDate":"2025-09","conditions":"Rheumatic Disease","enrollment":80},{"nctId":"NCT07021495","phase":"","title":"SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2025-07-29","conditions":"Chronic Spontaneous Urticaria (CSU), Hidradenitis Suppurativa (HS), Psoriasis (PsO)","enrollment":840},{"nctId":"NCT06676384","phase":"PHASE4","title":"Which of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve the Slope of Estimated Glomerular Filtration Rate at Two Years When Compared to Standard of Care Alone in South-Asian Kidney Biopsy-proven Adult (≥18 Years) Primary IgA Nephropathy?","status":"RECRUITING","sponsor":"Christian Medical College, Vellore, India","startDate":"2025-02-15","conditions":"IgA Nephropathy, Renal Insufficiency, Chronic, IgA Vasculitis","enrollment":585},{"nctId":"NCT07061717","phase":"PHASE3","title":"Comparing Endocrine Therapy Combined With High-Dose Palbociclib and Hydroxychloroquine to Endocrine Therapy Combined With Standard-Dose Palbociclib for Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2025-07-01","conditions":"Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer","enrollment":474},{"nctId":"NCT03979651","phase":"NA","title":"MEK and Autophagy Inhibition in Metastatic/Locally Advanced, Unresectable Neuroblastoma RAS (NRAS) Melanoma","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2019-10-15","conditions":"Metastatic NRAS Melanoma","enrollment":29},{"nctId":"NCT05119140","phase":"PHASE1, PHASE2","title":"Administration of Hydroxychloroquine (Plaquenil) to African Americans and Hispanics for the Treatment of Mild to Severe Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2022-06-10","conditions":"Ulcerative Colitis (Disorder)","enrollment":3},{"nctId":"NCT06768294","phase":"PHASE2","title":"Baricitinib in CPPD - the BAPTIST Study","status":"NOT_YET_RECRUITING","sponsor":"I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio","startDate":"2025-01","conditions":"Calcium Pyrophosphate Deposition Disease, Chondrocalcinosis","enrollment":32},{"nctId":"NCT05714670","phase":"PHASE2","title":"The Effect of Curcumin on the Clinical Outcome of Pediatric Patients with Active Lupus Nephritis","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2023-04-01","conditions":"Lupus Nephritis, SLE Nephritis","enrollment":72},{"nctId":"NCT04310462","phase":"NA","title":"Effectiveness of an EHR Interface to Reduce Dosage of Hydroxychloroquine","status":"TERMINATED","sponsor":"University of California, San Francisco","startDate":"2017-02-01","conditions":"Rheumatic Diseases","enrollment":65},{"nctId":"NCT04315948","phase":"PHASE3","title":"Trial of Treatments for COVID-19 in Hospitalized Adults","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2020-03-22","conditions":"Corona Virus Infection","enrollment":1552},{"nctId":"NCT04390152","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Intravenous Wharton's Jelly Derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Due to COVID 19","status":"TERMINATED","sponsor":"BioXcellerator","startDate":"2020-01-13","conditions":"Acute Respiratory Distress Syndrome","enrollment":6},{"nctId":"NCT06512753","phase":"","title":"The Effectiveness of Hydroxychloroquine Versus Methotrexate in the Treatment of Lichen Planopilaris in Routine Clinical Care: a Patient Preference Trial","status":"RECRUITING","sponsor":"Erasmus Medical Center","startDate":"2024-07-01","conditions":"Lichen Planopilaris, Cicatricial Alopecia","enrollment":56},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT04390594","phase":"PHASE3","title":"Efficacy and Safety Evaluation of Treatment Regimens in Adult COVID-19 Patients in Senegal","status":"TERMINATED","sponsor":"Institut Pasteur de Dakar","startDate":"2020-08-13","conditions":"COVID-19","enrollment":59},{"nctId":"NCT04809623","phase":"PHASE1","title":"Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2021-09-01","conditions":"Cutaneous Lupus Erythematosus","enrollment":3},{"nctId":"NCT06229340","phase":"PHASE2","title":"Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations","status":"RECRUITING","sponsor":"N.N. Petrov National Medical Research Center of Oncology","startDate":"2023-10-03","conditions":"RAS Mutation, Ras (Kras or Nras) Gene Mutation, Colorectal Cancer Recurrent","enrollment":20},{"nctId":"NCT04381936","phase":"PHASE3","title":"Randomised Evaluation of COVID-19 Therapy","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2020-03-19","conditions":"Severe Acute Respiratory Syndrome","enrollment":70000},{"nctId":"NCT05899907","phase":"PHASE4","title":"Efficacy and Safety of Telitacicept in Early SLE","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2022-09-01","conditions":"Lupus Erythematosus, Systemic","enrollment":180},{"nctId":"NCT05644210","phase":"","title":"Telitacicept Followed With Rituximab Therapy on APS Secondary to SLE","status":"UNKNOWN","sponsor":"Qilu Hospital of Shandong University","startDate":"2022-10-01","conditions":"Antiphospholipid Syndrome","enrollment":80},{"nctId":"NCT04335305","phase":"PHASE2","title":"Checkpoint Blockade in COVID-19 Pandemic","status":"TERMINATED","sponsor":"MedSIR","startDate":"2020-04-09","conditions":"COVID-19, Pneumonia, Viral","enrollment":12},{"nctId":"NCT04341441","phase":"PHASE3","title":"Will Hydroxychloroquine Impede or Prevent COVID-19","status":"TERMINATED","sponsor":"Henry Ford Health System","startDate":"2020-04-07","conditions":"COVID-19, Coronavirus, Coronavirus Infections","enrollment":624},{"nctId":"NCT05302947","phase":"","title":"COVID-19 Study at the Russian Clinical and Research Center of Gerontology of the Pirogov RNRMU","status":"COMPLETED","sponsor":"Pirogov Russian National Research Medical University","startDate":"2020-02-01","conditions":"COVID-19, Mild to Moderate","enrollment":154},{"nctId":"NCT04374539","phase":"PHASE2","title":"Plasma Exchange in Patients With COVID-19 Disease and Invasive Mechanical Ventilation: a Randomized Controlled Trial","status":"TERMINATED","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2020-04-29","conditions":"Coronavirus","enrollment":36},{"nctId":"NCT04394182","phase":"NA","title":"Ultra Low Doses of Therapy With Radiation Applicated to COVID-19","status":"SUSPENDED","sponsor":"Fundacion GenesisCare","startDate":"2020-04-21","conditions":"Pneumonia, Viral, Cytokine Storm","enrollment":15},{"nctId":"NCT05024006","phase":"NA","title":"Public Health Emergency: SOLIDARITY TRIAL Philippines","status":"COMPLETED","sponsor":"University of the Philippines","startDate":"2020-04-23","conditions":"Covid19","enrollment":1314},{"nctId":"NCT05247554","phase":"PHASE3","title":"Randomized Controlled Trial of Hydroxychloroquine Combined With Low-dose Corticosteroid in Pulmonary Sarcoidosis","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2022-03-01","conditions":"Pulmonary Sarcoidosis","enrollment":200},{"nctId":"NCT05237843","phase":"PHASE1","title":"Hydroxychloroquine in Unexplained Recurrent Pregnancy Loss","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2022-03-01","conditions":"Recurrent Pregnancy Loss","enrollment":70},{"nctId":"NCT03122431","phase":"PHASE4","title":"Relevance of Monitoring Blood and Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases","status":"COMPLETED","sponsor":"University of Sao Paulo General Hospital","startDate":"2017-06-05","conditions":"Systemic Lupus Erythematosus (SLE), Juvenile SLE, Cutaneous Lupus","enrollment":93},{"nctId":"NCT04414241","phase":"PHASE3","title":"Hydroxychloroquine to Prevent SARS-CoV-2 Infection/COVID-19","status":"COMPLETED","sponsor":"Universidad Peruana Cayetano Heredia","startDate":"2020-06-25","conditions":"SARS-CoV-2","enrollment":68},{"nctId":"NCT04346693","phase":"PHASE3","title":"An Open Randomized Study of Dalargin Efectiveness in Combination With Leitragin Drug in Patients With Severe and Critical Manifestations of SARS-COVID-19","status":"COMPLETED","sponsor":"Burnasyan Federal Medical Biophysical Center","startDate":"2020-04-08","conditions":"Acute Respiratory Tract Infection, Acute Respiratory Insufficiency, Pneumonia","enrollment":320},{"nctId":"NCT01784523","phase":"PHASE3","title":"Hydroxychloroquine for the First Thrombosis Prevention in Antiphospholipid Antibody Positive Patients","status":"TERMINATED","sponsor":"Hospital for Special Surgery, New York","startDate":"2013-02","conditions":"Antiphospholipid Syndrome","enrollment":11},{"nctId":"NCT05004753","phase":"PHASE4","title":"A Study to Evaluate the Safety and Efficacy of Artemisinin- a Herbal Supplement on COVID-19 Subjects","status":"COMPLETED","sponsor":"Mateon Therapeutics","startDate":"2020-09-30","conditions":"Covid19","enrollment":120},{"nctId":"NCT04392973","phase":"NA","title":"FAvipiravir and HydroxyChloroquine Combination Therapy","status":"COMPLETED","sponsor":"King Abdullah International Medical Research Center","startDate":"2020-05-21","conditions":"COVID19","enrollment":268},{"nctId":"NCT04347980","phase":"PHASE3","title":"Dexamethasone Treatment for Severe Acute Respiratory Distress Syndrome Induced by COVID-19","status":"TERMINATED","sponsor":"Centre Chirurgical Marie Lannelongue","startDate":"2020-04-17","conditions":"Respiratory Distress Syndrome, Adult, COVID-19","enrollment":5},{"nctId":"NCT04353180","phase":"PHASE3","title":"Assessment the Activity Value of Isotretinoin (13- Cis-Retinoic Acid ) in the Treatment of COVID-19 ( Isotretinoin in Treatment of COVID-19) (Randomized)","status":"UNKNOWN","sponsor":"Kafrelsheikh University","startDate":"2021-08","conditions":"COVID19","enrollment":100000},{"nctId":"NCT04933864","phase":"PHASE1","title":"COVID-19 Treatment Using Methylene Blue and Photodynamic Therapy","status":"COMPLETED","sponsor":"I.M. Sechenov First Moscow State Medical University","startDate":"2020-04-24","conditions":"SARS-CoV-2","enrollment":60},{"nctId":"NCT04858633","phase":"PHASE3","title":"Hydroxychloroquine (HCQ) as Post Exposure Prophylaxis (PEP) for Prevention of COVID-19","status":"UNKNOWN","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2021-03-22","conditions":"Covid19, COVID-19 Prevention","enrollment":1000},{"nctId":"NCT04335552","phase":"PHASE2","title":"Pragmatic Factorial Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection","status":"TERMINATED","sponsor":"Duke University","startDate":"2020-04-17","conditions":"SARS-CoV-2","enrollment":11},{"nctId":"NCT04853901","phase":"PHASE3","title":"Remdesivir Efficacy In Management Of COVID-19 Patients","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2020-07-27","conditions":"Covid19","enrollment":77},{"nctId":"NCT04351191","phase":"PHASE4","title":"PRophylaxis of Exposed COVID-19 Individuals With Mild Symptoms Using choloroquinE Compounds","status":"TERMINATED","sponsor":"Government of Punjab, Specialized Healthcare and Medical Education Department","startDate":"2020-04-15","conditions":"Sars-CoV2, Symptomatic Condition, Covid-19","enrollment":137},{"nctId":"NCT04346667","phase":"PHASE4","title":"Post-Exposure Prophylaxis for Asymptomatic SARS-CoV-2 COVID-19 Patients With choloroquinE Compounds","status":"TERMINATED","sponsor":"Government of Punjab, Specialized Healthcare and Medical Education Department","startDate":"2020-04-14","conditions":"SARS-CoV-2, Coronavirus Infection, Asymptomatic Condition","enrollment":125},{"nctId":"NCT04788355","phase":"PHASE3","title":"Prevention of Complications (SARS-CoV-2): Clinical Study","status":"COMPLETED","sponsor":"Universidade do Vale do Sapucai","startDate":"2020-07-01","conditions":"Complication","enrollment":176},{"nctId":"NCT04351724","phase":"PHASE2, PHASE3","title":"Austrian CoronaVirus Adaptive Clinical Trial (COVID-19)","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2020-04-16","conditions":"COVID-19","enrollment":500},{"nctId":"NCT04746365","phase":"PHASE4","title":"Ivermectin Role in Covid-19 Clinical Trial","status":"COMPLETED","sponsor":"Elaraby Hospital","startDate":"2020-12-06","conditions":"Covid19","enrollment":300},{"nctId":"NCT04646109","phase":"PHASE3","title":"Ivermectin for Severe COVID-19 Management","status":"COMPLETED","sponsor":"Afyonkarahisar Health Sciences University","startDate":"2020-05-11","conditions":"COVID-19","enrollment":66},{"nctId":"NCT04386447","phase":"PHASE2","title":"Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19","status":"WITHDRAWN","sponsor":"Azienda Ospedaliero-Universitaria di Parma","startDate":"2020-09-01","conditions":"Covid-19, Corona Virus Infection, SARS-CoV 2","enrollment":""},{"nctId":"NCT04403646","phase":"NA","title":"Tannin Specific Natural Extract for COVID-19 Infection","status":"TERMINATED","sponsor":"Hospital de Clinicas José de San Martín","startDate":"2020-06-12","conditions":"COVID-19, SARS-CoV 2, Coronavirus Infection","enrollment":124},{"nctId":"NCT04668469","phase":"NA","title":"Efficacy and Safety of Ivermectin for Treatment and Prophylaxis of COVID-19 Pandemic","status":"COMPLETED","sponsor":"Benha University","startDate":"2020-06-08","conditions":"Covid19","enrollment":600},{"nctId":"NCT04364815","phase":"PHASE3","title":"The University of the Philippines Hydroxychloroquine PEP Against COVID-19 Trial","status":"WITHDRAWN","sponsor":"University of the Philippines","startDate":"2020-12","conditions":"COVID-19","enrollment":""},{"nctId":"NCT04597775","phase":"PHASE2, PHASE3","title":"Chemoprevention Clinical Trial of COVID-19: Hydroxychloroquine Post Exposure Prophylaxis","status":"UNKNOWN","sponsor":"Regional Center for Disease Control and Prevention, Jordan","startDate":"2020-10-27","conditions":"SARS-CoV Infection","enrollment":93},{"nctId":"NCT04342156","phase":"PHASE3","title":"Safety And Efficacy Of Hydroxychloroquine For At Risk Population (SHARP) Against COVID-19","status":"WITHDRAWN","sponsor":"Tan Tock Seng Hospital","startDate":"2020-04","conditions":"Coronavirus Infection, Hydroxychloroquine Adverse Reaction","enrollment":""},{"nctId":"NCT04361422","phase":"PHASE3","title":"Isotretinoin in Treatment of COVID-19","status":"UNKNOWN","sponsor":"Tanta University","startDate":"2020-12-01","conditions":"COVID-19","enrollment":300},{"nctId":"NCT04558463","phase":"PHASE3","title":"The Effectivity and Safety of Favipiravir Compared to Oseltamivir as Adjuvant Therapy for COVID-19","status":"UNKNOWN","sponsor":"Indonesia University","startDate":"2020-04-16","conditions":"Covid19","enrollment":100},{"nctId":"NCT04334967","phase":"PHASE4","title":"Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care","status":"SUSPENDED","sponsor":"Providence Health & Services","startDate":"2020-03-30","conditions":"COVID-19, Corona Virus Infection, SARS-CoV-2","enrollment":13},{"nctId":"NCT04528927","phase":"PHASE3","title":"Evaluation of the Efficacy and Safety of Treatments for Patients Hospitalized for COVID-19 Infection Without Signs of Acute Respiratory Failure, in Tunisia","status":"WITHDRAWN","sponsor":"Abderrahmane Mami Hospital","startDate":"2020-05-15","conditions":"COVID 19, Patients Hospitalized","enrollment":""},{"nctId":"NCT04491994","phase":"PHASE3","title":"Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression","status":"COMPLETED","sponsor":"UNICEF","startDate":"2020-04-10","conditions":"Covid19, Progression","enrollment":540},{"nctId":"NCT04360759","phase":"PHASE3","title":"Chloroquine Outpatient Treatment Evaluation for HIV-Covid-19","status":"WITHDRAWN","sponsor":"University of Cape Town","startDate":"2020-05-01","conditions":"Covid-19, HIV","enrollment":""},{"nctId":"NCT04408456","phase":"PHASE3","title":"Efficacy of Hydroxychloroquine (HCQ) as Post Exposure Prophylaxis (PEP) for Prevention of COVID-19","status":"COMPLETED","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2020-03-01","conditions":"CoVID-19","enrollment":325},{"nctId":"NCT04395170","phase":"PHASE2, PHASE3","title":"Convalescent Plasma (PC) and Human Intravenous Anti-COVID-19 Immunoglobulin (IV Anti COVID-19 IgG) in Patients Hospitalized for COVID-19.","status":"UNKNOWN","sponsor":"Lifefactors Zona Franca, SAS","startDate":"2020-09","conditions":"Coronavirus Disease 2019 (COVID-19)","enrollment":75},{"nctId":"NCT04349241","phase":"PHASE3","title":"Efficacy and Safety of Favipiravir in Management of COVID-19","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2020-04-18","conditions":"Coronavirus Disease (COVID-19)","enrollment":100},{"nctId":"NCT04443725","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of Anti HCV Drugs in the Treatment of COVID-19","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2020-07","conditions":"COVID-19","enrollment":100},{"nctId":"NCT04362332","phase":"PHASE4","title":"Chloroquine, Hydroxychloroquine or Only Supportive Care in Patients AdmItted With Moderate to Severe COVID-19","status":"TERMINATED","sponsor":"UMC Utrecht","startDate":"2020-04-14","conditions":"COVID-19","enrollment":25},{"nctId":"NCT04434248","phase":"PHASE2, PHASE3","title":"An Adaptive Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19","status":"UNKNOWN","sponsor":"Chromis LLC","startDate":"2020-04-23","conditions":"COVID-19","enrollment":330},{"nctId":"NCT04347512","phase":"PHASE3","title":"EVALUATION OF THE EFFICACY OF THE HYDROXYCHLOROQUINE-AZITHROMYCIN COMBINATION IN THE IN THE PREVENTION OF COVID-19 RELATED SDRA","status":"WITHDRAWN","sponsor":"University Hospital, Strasbourg, France","startDate":"2020-06-02","conditions":"Sars-CoV-2, Community-Acquired Pneumonia,COVID-19","enrollment":""},{"nctId":"NCT04374071","phase":"","title":"Early Short Course Corticosteroids in COVID-19","status":"COMPLETED","sponsor":"Henry Ford Health System","startDate":"2020-03-12","conditions":"COVID, Pneumonia, Viral","enrollment":250},{"nctId":"NCT04368351","phase":"","title":"Bacteriotherapy in the Treatment of COVID-19","status":"UNKNOWN","sponsor":"University of Roma La Sapienza","startDate":"2020-03-01","conditions":"COVID, Pneumonia, Diarrhea","enrollment":70},{"nctId":"NCT04366089","phase":"PHASE2","title":"Oxygen-Ozone as Adjuvant Treatment in Early Control of COVID-19 Progression and Modulation of the Gut Microbial Flora","status":"UNKNOWN","sponsor":"Roberto Poscia MD, PhD","startDate":"2020-03-26","conditions":"COVID, SARS-CoV 2, Pneumonia, Viral","enrollment":152},{"nctId":"NCT04323345","phase":"PHASE3","title":"Efficacy of Natural Honey Treatment in Patients With Novel Coronavirus","status":"UNKNOWN","sponsor":"Misr University for Science and Technology","startDate":"2020-04-15","conditions":"COVID-19","enrollment":1000},{"nctId":"NCT04350684","phase":"PHASE4","title":"Umifenovir in Hospitalized COVID-19 Patients","status":"UNKNOWN","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2020-04-15","conditions":"COVID-19","enrollment":40},{"nctId":"NCT04321616","phase":"PHASE2, PHASE3","title":"The Efficacy of Different Anti-viral Drugs in COVID 19 Infected Patients","status":"UNKNOWN","sponsor":"Oslo University Hospital","startDate":"2020-03-28","conditions":"SARS-CoV Infection, COVID 19, Acute Respiratory Distress Syndrome ARDS","enrollment":700},{"nctId":"NCT02433184","phase":"PHASE4","title":"Very Early Versus Delayed Etanercept in Patients With RA","status":"COMPLETED","sponsor":"University of Leeds","startDate":"2011-07","conditions":"Rheumatoid Arthritis","enrollment":120},{"nctId":"NCT03813771","phase":"PHASE4","title":"Targeted Treatment Early With Etanercept + Methotrexate vs.T2T Care for DMARD-naïve Early RA Patients Based on naïve T-cell Stratification","status":"UNKNOWN","sponsor":"University of Leeds","startDate":"2019-03","conditions":"Rheumatoid Arthritis","enrollment":106},{"nctId":"NCT03610217","phase":"NA","title":"Pragmatic Clinical Trials in Scleroderma","status":"UNKNOWN","sponsor":"University of West London","startDate":"2018-10","conditions":"Scleroderma, Systemic, Sclerosis, Systemic","enrollment":400},{"nctId":"NCT01015547","phase":"PHASE3","title":"Aggressive Combination Drug Therapy in Very Early Polyarticular Juvenile Idiopathic Arthritis","status":"COMPLETED","sponsor":"Helsinki University Central Hospital","startDate":"2003-05","conditions":"Juvenile Idiopathic Arthritis","enrollment":60},{"nctId":"NCT01272310","phase":"PHASE1, PHASE2","title":"Clinical Trial to Assess Safety and Efficacy of Combination Therapy: Hydroxychloroquine, Pegylated Interferon Alpha-2a and Ribavirin in Chronic Hepatitis C Subjects Non-responders to the Standard of Care Therapy.","status":"UNKNOWN","sponsor":"Sheba Medical Center","startDate":"2011-01","conditions":"Chronic Hepatitis C","enrollment":36}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["HCQ standard"],"phase":"marketed","status":"active","brandName":"standard dose of HCQ","genericName":"standard dose of HCQ","companyName":"University of Sao Paulo General Hospital","companyId":"university-of-sao-paulo-general-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Hydroxychloroquine is a quinoline antimalarial that accumulates in lysosomes and inhibits toll-like receptor signaling and antigen presentation, reducing inflammatory and autoimmune responses. Used for Systemic lupus erythematosus (SLE), Rheumatoid arthritis, Malaria prophylaxis and treatment.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}